Search - tctmd.com

Displaying 121 - 140 of 193

Sort: Relevancy | Date

Presentation TCT 2015

Does PEGASUS Inform the Debate?

Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Tullio Palmerini

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Laura Mauri

October 12, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Deepak L. Bhatt

October 12, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai

October 12, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Dimitrios Alexopoulos

October 12, 2015

Presentation TCT 2015

New Data: Results of the HEAT-PPCI Platelet Substudies

Presenter: Eric Boersma, E. Magnus Ohman, Rod H. Stables

October 12, 2015

$Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!$

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee

October 12, 2015

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas

October 12, 2015

Presentation TCT 2015

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Presenter: John A. Bittl, Robert A. Harrington, Mahesh Madhavan

October 12, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Debate: The Case for Short-term DAPT in Most Patients!

Presenter: Regina Deible, Gennaro Giustino

October 11, 2015

Presentation TCT 2015

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Presenter: Regina Deible, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Presenter: Regina Deible, Roxana Mehran

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Advertisement

Does PEGASUS Inform the Debate?

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

New Data: Results of the HEAT-PPCI Platelet Substudies

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Debate: The Case for Short-term DAPT in Most Patients!

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content